TENX earnings analysis
What we found in TENX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Tenax Therapeutics reported a challenging Q1 2026, with a net loss of $15.7 million, reflecting a significant increase in operating expenses primarily driven by rising R&D costs. The company's total cash position remains solid at $118.8 million, expected to fund operations until at least Q1 2028, despite a consistent trend of net losses across quarters.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Net Loss Increased
- The net loss for Q1 2026 was $15.7 million, a $5.3 million increase compared to $10.4 million in Q1 2025.
- R&D Expenses Surge
- Research and development expenses rose by $5.8 million to $11.5 million in Q1 2026 from $5.7 million in Q1 2025.
- Cash Position Solidified
- Tenax Therapeutics maintained a cash position of $118.8 million, sufficient to fund operations through at least Q1 2028.
- EPS Improvement
- The diluted EPS for Q1 2026 was -$0.35, better than the consensus estimate of -$0.40.
- Operating Cash Flow
- Net cash used in operating activities amounted to $9.3 million in Q1 2026, compared to $7.0 million in Q1 2025.
- Increased Financing Activities
- Received $30.5 million from financing activities in Q1 2026, up from $23.6 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Net Operating Loss
- Net loss increased by 51% to $15.7 million in Q1 2026 from $10.4 million in Q1 2025.
- Escalating R&D Costs
- R&D expenses jumped by 102% year-over-year, increasing to $11.5 million in Q1 2026.
- Clinical Trial Execution Risks
- Continued reliance on successful completion of clinical trials, which are unpredictable and costly.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.35
What they said about what is next.
No specific quantitative guidance provided.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TENX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever